Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Antibody manufacture in transgenic animals and comparisons with other systems
Louis-Marie Houdebine

Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. The isolation and engineering of the corresponding genes is becoming less of a bottleneck in the process; however, the production of recombinant antibodies is itself a limiting factor and a shortage is expected in the coming years. Milk from transgenic animals appears to be one of the most attractive sources of recombinant antibodies. None of the production systems presently implemented (CHO cells, insect cells infected by baculovirus, or transgenic animals and plants) has yet been optimized. This review describes the advantages of using milk for antibody production in comparison with the other systems.

Introduction

Animals are the natural producers of the antibodies they use for protection against diseases. Vaccination and passive immunization exploit this property extensively. The great variety of antibodies, as well as their high specificity and affinity for antigens, makes it possible to use these molecules for purposes other than passive protection against diseases. Indeed, antibodies are one of the favourite tools of biologists and are extensively used for various in vivo and in vitro diagnostics. Antibodies may also have natural enzymatic activities, which can be optimized by mutations [1]. These antibodies, known as abzymes, might become a new source of enzymes. Furthermore, antibodies could be used to manage environmental pollution by neutralizing toxic substances [2].

The major uses of monoclonal antibodies are expected to be in the medical domain. For example, the administration of recombinant antibodies can be used to protect patients against respiratory syncytial virus infection [3]. Such an approach is particularly attractive when no vaccines or antibiotics are available or when the pathogens have become resistant to antibiotics [4]. Interestingly, not only IgG but complete recombinant chimaeric IgA can also be used to inactivate pathogens in patients [5]. Antibodies can also mediate protection against intracellular pathogens [6]. In this respect, they could provide a major line of defence against biological attack by terrorists [4], particularly as they can be kept as a powder and easily self-injected in case of attack.

Antibodies neutralize pathogens via different mechanisms. A simple binding of the antibody to a key molecule of the pathogen may be sufficient to provide protection. In other cases, antibody-dependent cellular cytotoxicity (ADCC) is needed [7••]. Recent studies have shown that the simultaneous use of monoclonal antibodies directed against several different conformational epitopes of the human immunodeficiency virus envelope, which binds CD4 in human lymphocytes, prevented infection by various mutants of the virus [8]. Antibodies can specifically block the action of natural factors in vivo, and are used to inhibit some rejection mechanisms after organ transplantation.

Antibodies can also be used as vehicles to target active molecules to specific cells. For example, radioactive ions can be bound to antibodies that specifically recognize tumour cells. This approach proved to destroy Hodgkin’s [9] and non-Hodgkin’s lymphoma [10]. Toxins bound to antibodies can have similar effects [11].

The versatility of antibodies is further demonstrated by their use in transfection studies. Plasmids can be non-covalently bound to antibodies and these complexes allow for efficient and specific in vivo transfection. This method, called antifection [12], was used to destroy human tumours grafted to severe combined immunodeficiency disease (SCID) mice: genes that induce cell death by apoptosis were used for this purpose. Other ‘killer’ genes can also be used (F Hirsch et al., personal communication). The same approach may be extended to tumour cell genes coding for enzymes capable of locally transforming a prodrug into an active antitumour molecule. This versatile method could also provide cells with genes coding for growth factors, leading to tissue regeneration.

As can be seen, antibodies have a vast range of uses both in vivo and in vitro, all of which require different forms of these molecules. Methods for efficient antibody production are therefore of significant interest to biotechnologists. In this review we consider some of the advantages and disadvantages of the available antibody expression systems and discuss future considerations.

Antibody gene isolation and engineering

Complete antibodies or monovalent or bivalent fragments can be synthesized and used for many of the application
described above. Antibodies can be murine, chimaeric (i.e. largely murine but containing the human constant region) or humanized. In the case of humanized antibodies, only the regions that recognize the antigen are not of human origin [13]. Humanization minimizes as much as possible the immune reactions of patients against the injected antibodies. Antibodies produced in this way may be IgGs, which contain light and heavy chains, or IgAs which have, in addition to heavy and light chains, a junction chain and a secretory component. Ideally, the production system should provide antibodies requiring no modifications before use.

The vast majority of monoclonal antibodies used to date are of murine origin. Rabbits, which have a broad antibody repertoire, are a possible alternative, but both of these approaches require antibody humanization [14].

The most attractive strategy is to prepare human monoclonal antibodies; however, the cloning of the corresponding genes from human cells has proved to be difficult. Phage display [15] or polyoma display [13] allow the systematic cloning of genes or gene fragments coding for heavy or light chains, which are capable of forming functional antibodies after their random association. These approaches may require laborious antibody mutations in order to obtain the appropriate specificity and affinity.

Pioneering work showed that recombinant antibodies could be obtained from the blood of transgenic animals [16,17]. However, these antibodies were hybrids containing host chains. Nevertheless, antibodies obtained using this approach were able to protect fish against haemorrhagic septicaemia virus [18] and mice against prion disease [19].

The simplest way to obtain human antibody genes is to use transgenic mice. These animals harbour human Ig loci and their own Ig loci have been eliminated by homologous recombination [20–22]. These ‘immunized’ mice can potentially provide most of the human antibodies required for human therapy (see also Update).

**Antibody expression systems**

Several studies have concluded that bacteria and yeast are only suitable for the synthesis of antibody fragments. By contrast, insect cells and Chinese hamster ovary (CHO) cells can be the source of intact antibodies fully capable of recognizing antigens [23,24*,25].

Cultured cells, even when optimized, are expected to have limited capacity to produce large amounts of antibodies [23,24*,25,26**]. Transgenic animals and plants appear to be the only tools enabling high production levels [26**,27–29,30**].

Animal and plant cells have a similar capacity to assemble antibody subunits and active IgAs were prepared from plants [27] as well as from CHO cells [25]. However, these systems are not equivalent as far as the post-translational modifications of antibodies are concerned. The different systems vary in their capacity to glycosylate antibodies. This point is essential, as glycosylation is required to obtain antibodies that are stable in vivo and capable of inducing complement and ADCC [31].

Antibodies extracted from plants (so-called plantibodies) have N-glycans that are very different from those secreted by mammalian cells [32,33]. The N-glycans of plantibodies are not only unable to provide them with some biological properties, but might also induce various undesirable side-effects in patients. Preliminary data indicate that plantibodies in mice do not provoke a significant immune response [33], or at least not after a limited number of injections, but additional studies will be required before this problem can be considered to be negligible.

Murine IgGs prepared from tobacco were able to prevent tooth infection by Streptococcus mutans in mice without causing any side-effects [34]. Interestingly, human anti-Rhesus D IgG1 antibody produced in Arabidopsis inactivated Rhesus-D antigen even though natural killer (NK)-mediated ADCC did not occur. Thus, unexpectedly, this inactivating effect seems to be mediated by a mechanism different from ADCC. This suggests that plantibodies might have a broader pattern of therapeutic activity than anticipated [35].

Native proteins are often heterogeneously glycosylated. This phenomenon occurs on a greater scale in recombinant proteins secreted from CHO cells or mammary glands [36]. This seems to be due to a saturation of the glycosylation machinery, as recombinant proteins are less completely glycosylated when their concentration in milk is higher. The under-glycosylated antibodies may be less stable in vivo and might not have all the expected biological properties.

Plantibodies are not sialylated. Antibodies found in CHO culture medium and in milk are only partially sialylated. Sialic acid exists in two forms: N-glycosylneuraminic acid (NGNA) and N-acetylaneuraminic acid (NANA). Human proteins contain the NGNA form of sialic acid and ruminant proteins the NANA form, whereas rabbit proteins have both forms and chicken proteins only the NANA form [37]. It is expected that antibodies with the NGNA form of sialic acid could provoke some undesirable side-effects including immune response in patients.

NK-mediated ADCC is known to be induced by antibodies only if the N-glycans grafted to Asp297 in the human constant region of the antibody is properly glycosylated. The presence of N-acetylgalactosamine (GlcNac) in the triantennary N-glycan is also thought to be required for inducing ADCC. It is known that plant cells do not add GlcNac and that this is also the case for several types of animal cell. The presence of terminal GlcNac in recombinant antibodies extracted from milk has not been documented so far.
Glycosylation of antibodies can be improved in plants and animals by transferring the genes encoding enzymes capable of adding GlcNac, sialic acid, fucose and galactose to the N-glycans. This has been achieved in CHO cells [38••,39••] and is under study in plants [32] and animals.

The production of a few monoclonal antibodies in milk has been documented [30••]. Mouse monoclonal antibodies, both humanized and non-humanized, that are capable of neutralizing coronavirus have been produced in mouse milk at a concentration of up to several grams per litre [40,41].

Anti-CD6 [42], anti-CD19 [43] present on the cell surface, and antitransferrin receptor–RNase fusion protein [44] have been prepared in mouse milk. Several antibodies from goat milk are also available [30••].

Protein purification is known to be a key stage in the preparation of biopharmaceuticals. The culture medium of CHO cells may contain cell debris, lipids, DNA, cellular proteins, viruses and other pathogens and, potentially, serum albumin, transferrin and serum. Immunoglobulin purification from milk does not raise particular problems: lipids are eliminated in an early step by centrifugation and caseins and lactose can be separated from immunoglobulin by membrane filtration. Affinity chromatography exchangers can provide antibodies with 99.9% purity with a yield of 65% [30••]. The presence of host animal IgG and IgA in milk may complicate the purification protocol in some cases. Available chromatographic systems have given satisfactory results so far.

Antibody purification from plants can be achieved with existing methods. The problems that are encountered are different when antibodies are stored in seeds rather than in leaves. It is acknowledged that it may be more difficult to separate antibodies from seed proteins than from leaf cellular proteins; however, products extracted from leaves are more likely to contain contaminants that will have undesirable side-effects when injected into patients.

Conclusions
The available data leave little doubt as to the capacity of CHO cells and transgenic plants and animals for the large-scale preparation of diverse recombinant antibodies. Different experts have their own view on the advantages and limitations of these different systems, but the data are still too scarce to allow precise conclusions. It is claimed that up to 10 kg of recombinant antibodies per acre can be obtained from transgenic plants [27]. Grams of antibodies per litre of milk have been repeatedly obtained. Optimization of vectors and, particularly, the use of gene insulators will allow increased and more predictable production of antibodies in milk [45]. Recent work has shown that loci are bordered by DNA regions insulating their genes from those of the neighbouring loci. The known insulators contain silencers preventing cross-talk between genes of neighbouring loci, chromatin openers to give free access to the transcription machinery, and enhancers [46]. One insulator from the chicken β-globin locus allowed most if not all transgenic lines to express foreign genes under the control of a ubiquitous promoter [47] and a milk protein gene promoter (S Rival-Gervier, unpublished results). Interestingly, long genomic DNA fragments containing two independent milk protein genes (α-lactalbumin and whey acidic protein) allowed the highly efficient expression of these genes in transgenic mice [48–50]. These data strongly suggest that the long DNA fragments contained insulators, which can be associated to gene constructs to optimize their expression in milk. Although CHO cells have a more limited production capacity, they could still provide a cheaper production system than goat milk for quantities ranging from 10 to 50 kg per year [51].

Transgenic plants are expected to provide up to 1 kg of plantibodies after 36 months [28]. The same levels could be obtained from rabbit milk, but not from goat milk.

One advantage of transgenic plants and animals over CHO cells is their flexibility. Building a 100 000 L fermentor requires four years and costs $400 million [7••]. Scaling up production in CHO cells is therefore much more difficult than simply using more plants or animals.

An argument commonly used as a reason to favour the use of transgenic plants rather than animals to produce recombinant antibodies is that plants are devoid of human pathogens. The reality is more subtle: it is possible to breed animals in conditions where they are not subjected to infections [52••]. Animals can be bred that are not contaminated by prions and the presence of prions in purified proteins can be detected. In the future, animals with an inactive prion protein gene could be available. One species, the rabbit, is known to transmit only rare and minor diseases to humans. Moreover, this animal is not susceptible to prion diseases and may prove useful for antibody production in the future.

In view of concerns about infection, the US Food and Drug Administration and the European Medicines Evaluation Agency have laid down points to consider when preparing recombinant proteins from milk. These guidelines do not appear to be a bottleneck when using animals for the preparation of recombinant antibodies.

One of the major advantages of transgenic plants and animals over cultured cells is their robustness. Domestic transgenic plants and animals can be maintained in already defined standard conditions and their levels of production are very stable. Milk secretion is essentially constant for weeks or months (depending on the species) and the same is true for the secretion of recombinant proteins in milk. In cell culture, protein glycosylation is known to be dependent on CHO metabolism, which is variable according to...
culture conditions [24•,31]. By contrast, the metabolism of
the mammary cell is much more stable and the glycosylation of
the recombinant protein secreted in milk is constant for
weeks or months. Lines of transgenic plants and animals
can be preserved using well-known techniques. Seeds and
milk can be easily stored until it is time to purify the antici-
without any loss of activity.

Transgenic plants producing antibodies may raise environ-
mental concerns. Indeed, plants cultured in fields could
release recombinant proteins that have an effect in humans.
Furthermore, transgenic plants are acknowledged to dissemin-
ate their genes in neighbouring fields in an uncontrolled
manner. This phenomenon is expected to have a negligible
impact for agriculture in most cases. The situation is quite
different for pharmaceutical-producing plants. These envi-
ronmental problems are expected to be solved using systems
to control plant reproduction. Such problems are unlikely to
be encountered with farm animals, which are kept in enclosed
areas. Biological fluids, other than milk, from transgenic
animals can theoretically be the source of pharmaceutical
proteins [53]. Among these systems, egg white from trans-
genetic chickens appears the most attractive [54] (see also
Update). At present, the production of antibodies in milk is
more technically mature than other systems using transgenic
animals, including chickens [54] or plants [27].

At this time, 11 recombinant antibodies have been approved
by the Food and Drug Administration. About 400 have been
prepared in different ways and are currently under testing.
The present total worldwide capacity for the production of
recombinant proteins in cultured cells is estimated to be
400 000 L, but about five to six times this capacity will be
encountered with farm animals, which are kept in enclosed
areas. Biological fluids, other than milk, from transgenic
animals can theoretically be the source of pharmaceutical
proteins [53]. Among these systems, egg white from trans-
genetic chickens appears the most attractive [54] (see also
Update). At present, the production of antibodies in milk is
more technically mature than other systems using transgenic
animals, including chickens [54] or plants [27].

Update

The production of recombinant antibodies is now being
extended to cow. A single human artificial chromosome
harbouring the unrearranged human heavy (H) and lamb-
da (L) chain loci has been introduced into the cow genome
using micro cell- mediated chromosome transfer and
cloning techniques. Mature and functional human
immunoglobulins were found in the blood of the trans-
schromosomic calf [55,56]. A recent review by Dove [57]
gives additional data supporting the idea that transgenic
animals are an inevitable tool to produce the needed recombinant antibodies in the coming years.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
**of outstanding interest

1. Fletcher MC, Kuderova A, Cygler M, Lee JS: Creation of a
ribonuclease abzyme through site-directed mutagenesis. Nat
Biotechnol 1998, 16:1065-1067.

2. Harris B: Exploiting antibody-based technologies to manage
environmental pollution. Trends Biotechnol 1999, 17:290-295.

3. Simoes EA: Respiratory syncytial virus infection. Lancet 1999,
354:847-852.

4. Casadevall A: Antibodies for defense against biological attack.
Nat Biotechnol 2002, 20:114.

5. Corthesy B: Recombinant immunoglobulin A: powerful tools for
fundamental and applied research. Trends Biotechnol 2002,
20:65-71.

6. Casadevall A: Antibody-mediated protection against intracellular
pathogens. Trends Microbiol 1998, 6:102-107.

7. Gura T: Therapeutic antibodies: magic bullets hit the target.
Nature 2002, 417:584-586.

8. Summarizing recent data, the author reports arguments favouring the idea
that the therapeutic use of recombinant antibodies is greatly increasing with
the result that production capacity is becoming quite insufficient.

9. Ferrantelli F, Ruprecht RM: Neutralizing antibodies against HIV —
back in the major league? Curr Opin Immunol 2002, 14:395-502.

10. Quadri SM, Lai J, Mohammadpour H, Wiesendorn HM, Williams JR:
Assessment of radioleabeled stabilized Fab(2) fragments of
monoclonal antiferritin in nude mouse model. J Nucl Med 1993,
34:2152-2159.

11. Webber D: Lymphoma Mabs rivalry continues. Nat Biotechnol
1998, 16:1006-1001.

12. Rader C, Ritter G, Nathan S, Elia M, Gout I, Jungbluth AA, Cohen LS,
Palmiter RD, Brinster RL: Expression of mouse IgA by transgenic
mice, pigs and sheep. Eur J Immunol 1999, 3:731-738.

13. Hudson PJ: Recombinant antibody fragments. Curr Opin Biotechnol
1998, 9:395-402.

14. Lopez B, Lenh Z, Brem G: The rabbit antibody repertoire as a
novel source for the generation of therapeutic human antibodies.
J Biol Chem 2000, 275:13668-13676.

15. Hub GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegeren L,
Boel E, van der Vaart de Vries AR, Loyzon SA, Helfrich W,
van Berge Henegouwen GP et al.: A recombinant, fully human
monoclonal antibody coupled to ricin A chain-derived peptides on
endothelial cells in vitro: insights into toxin-mediated vascular
damage. Exp Cell Res 2000, 258:417-424.

16. Poncet P, Panczak A, Gustafson C, Blanpied C, Chavanel V, Hirsch R, Hirsch F: Antifection: an antibody-mediated
method to introduce genes into lymphoid cells in vitro and in vivo.
Gene Ther 1996, 3:731-738.

17. Lo D, Pursel V, Linton PJ, Sandgren E, Behringer R, Ravindra C,
Palmiter R D, Brinster RL: Expression of mouse IgA by transgenic
mice, pigs and sheep. Eur J Immunol 1999, 21:1001-1006.

18. Weidle UH, Lenz H, Brem G: Genes encoding a mouse monoclonal
antibody are expressed in transgenic mice, rabbits and pigs. Gene
1991, 98:185-191.

19. Lorenzen N, Cupit PM, Emerjensen K, Lorenzen E, Ahrens P,
Scenesby CJ, Cunningham C: Immunophosphorylation in fish by
injection of mouse antibody genes. Nat Biotechnol 2000,
18:1177-1180.

20. Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B,
Zinkernagel RM, Kalinke U, Aguaz: Prevention of scrapie
pathogenesis by transgenic expression of anti-prion protein
antibodies. Science 2001, 294:178-182.

21. Jakobovits A: Production of fully human antibodies by transgenic
mice. Curr Opin Biotechnol 1995, 6:561-566.

22. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE,
Erickson KL, Yang XD, Gallo ML, Louie DM, Lee DV: Prevention of
scrapie pathogenesis by transgenic expression of anti-prion protein
antibodies. Nat Biotechnol 2000, 18:1177-1180.

23. Kost TA, Condrea JP: Recombinant baculoviruses as expression
vectors for insect and mammalian cells. Curr Opin Biotechnol
1999, 10:428-433.
Antibody manufacturing in transgenic animals  Houdébine 629

24. Andersen DC, Krummen L: Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 2002, 13:117-123.

25. Berenjoj, Blank CT, Reinhardt M, Krähenbühl J, Corthesy B: In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells. Proc Natl Acad Sci USA 1999, 96:29-34.

26. Andersson R, Mynahan R: The protein production challenge: in vivo. ** The Business and Medicine Report 2001, May 1-5.

The authors are Arthur D Little consultants who compared the capacity of the different production systems for recombinant antibodies. They also evaluated the total potency of these systems and the market in the coming years.

27. Lammick JW, Yu L, Walfazer C, Jaiswal S, Wycuff K: Production of secretory IgA antibodies in plants. Biomaol Eng 2001, 18:87-94.

28. Stoger E, Sack M, Fischer R, Christou P: CHO cells in biopharmaceutical production. Biotechnol J 2002, 13:161-166.

29. Houdébine LM: Transgenic animal bioreactors. Transgenic Res 2000, 9:305-320.

30. Pollock D, Kutzer J, Bricke-Wilson E, Williams J, Lecchel Y, ** Meade HM: Transgenic milk as a method for the production of recombinant antibodies. J Immunol Methods 1999, 231:147-157.

The authors have prepared more than 10 recombinant antibodies in mouse or goat milk. This article summarizes the different problems they faced and how they achieved success.

31. Wright A, Morrison SL: Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 1997, 15:26-32.

32. Faye L, Lerouge P, Gomord V: Market in the coming years.

33. Pollock D, Pollock D, DiTullio P, Echelard Y, Harvey M, Wilburn B, Williams J, Hoogenboom HR, Raus JC, Meade HM, Rybak SM: Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice. J Immunol Methods 1999, 231:159-167.

34. Weikert S, Papac D, Briggs J, Cowherd B, Well B: Biotechnological development of transgenic animals for production of recombinant proteins. J Immunol Methods 2000, 231:115-139.

35. Van Kuik-Romelin P, De Groot N, Hooijberg E, De Boer H: Expression of a functional mouse-human chimeric anti-CD19 antibody in the milk of transgenic mice. Transgenic Res 2000, 9:155-159.

36. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE: Transgenic milk as a method for the production of recombinant antibodies.

37. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG, Guszer M, Folsenfeld G: Position-effect protection and enhancer blocking by the chicken β-globin insulator are separable activities. Proc Natl Acad Sci USA 2000, 99:6883-6888.

38. Rebok-Dameron F, Malassagne B, Viglietta C, Puisant C, Leroux-Coyau M, Cherruau C, Alat J, Well B: Biotechnological development of transgenic animals for production of recombinant proteins.

39. Sola I, Castilla J, Pintado B, Sanchez-Morgado JM, Whitelaw CB, Clark AJ, Enjuanes L: Transgenic mice secreting coronavirus neutralizing antibodies into the milk. J Virol 1998, 72:3762-3772.

40. Castilla J, Pintado B, Sola I, Sanchez-Morgado JM, Enjuanes L: Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk. Nat Biotechnol 1998, 16:349-354.

41. Van Kuik-Romelin P, De Groot N, Hooijberg E, De Boer H: Expression of a functional mouse-human chimeric anti-CD19 antibody in the milk of transgenic mice. Transgenic Res 2000, 9:155-159.

42. Newton DL, Pollock D, DiTullio P, Echelard Y, Harvey M, Wilburn B, Williams J, Hoogenboom HR, Raus JC, Meade HM, Rybak SM: Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice. J Immunol Methods 1999, 231:159-167.

43. Houdebine LM, Altal J, Villoit J-L: Vector design for transgene expression. In Transgenic Animal Technology, Edn 2nd. Edited by Pinkert CA. Academic Press: London, UK; 2002, in press.

44. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG, Guszer M, Folsenfeld G: Position-effect protection and enhancer blocking by the chicken β-globin insulator are separable activities. Proc Natl Acad Sci USA 2000, 99:6883-6888.

45. Sola I, Castilla J, Pintado B, Sanchez-Morgado JM, Whitelaw CB, Clark AJ, Enjuanes L: Transgenic mice secreting coronavirus neutralizing antibodies into the milk. J Virol 1998, 72:3762-3772.

46. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG, Guszer M, Folsenfeld G: Position-effect protection and enhancer blocking by the chicken β-globin insulator are separable activities. Proc Natl Acad Sci USA 2000, 99:6883-6888.

47. Tabak-Dameron F, Malassagne B, Viglietta C, Puisant C, Leroux-Coyau M, Cherruau C, Alat J, Well B: Biotechnological development of transgenic animals for production of recombinant proteins.

48. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE: Transgenic milk as a method for the production of recombinant antibodies.

49. Sola I, Castilla J, Pintado B, Sanchez-Morgado JM, Whitelaw CB, Clark AJ, Enjuanes L: Transgenic mice secreting coronavirus neutralizing antibodies into the milk. J Virol 1998, 72:3762-3772.

50. Houdebine LM: Transgenic animal bioreactors. Transgenic Res 2000, 9:305-320.

51. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE: Transgenic milk as a method for the production of recombinant antibodies.

52. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG, Guszer M, Folsenfeld G: Position-effect protection and enhancer blocking by the chicken β-globin insulator are separable activities. Proc Natl Acad Sci USA 2000, 99:6883-6888.

53. Sola I, Castilla J, Pintado B, Sanchez-Morgado JM, Whitelaw CB, Clark AJ, Enjuanes L: Transgenic mice secreting coronavirus neutralizing antibodies into the milk. J Virol 1998, 72:3762-3772.

54. Houdebine LM: Transgenic animal bioreactors. Transgenic Res 2000, 9:305-320.

55. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE: Transgenic milk as a method for the production of recombinant antibodies.

56. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG, Guszer M, Folsenfeld G: Position-effect protection and enhancer blocking by the chicken β-globin insulator are separable activities. Proc Natl Acad Sci USA 2000, 99:6883-6888.

57. Sola I, Castilla J, Pintado B, Sanchez-Morgado JM, Whitelaw CB, Clark AJ, Enjuanes L: Transgenic mice secreting coronavirus neutralizing antibodies into the milk. J Virol 1998, 72:3762-3772.

58. Houdebine LM: Transgenic animal bioreactors. Transgenic Res 2000, 9:305-320.

59. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE: Transgenic milk as a method for the production of recombinant antibodies.